Entera Bio (NASDAQ:ENTX) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Entera Bio (NASDAQ:ENTX) in a research report released on Monday morning, Benzinga reports. The brokerage currently has a $10.00 target price on the stock. HC Wainwright also issued estimates for Entera Bio’s Q3 2024 earnings at ($0.05) EPS, Q4 2024 earnings at ($0.06) EPS, FY2024 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.53) EPS.

Entera Bio Trading Up 1.9 %

Shares of Entera Bio stock opened at $1.60 on Monday. The stock has a 50-day moving average price of $1.81 and a 200 day moving average price of $1.77. The company has a market cap of $57.26 million, a P/E ratio of -5.71 and a beta of 1.60. Entera Bio has a 1 year low of $0.52 and a 1 year high of $3.35.

Entera Bio (NASDAQ:ENTX) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.06). The business had revenue of $0.06 million during the quarter. On average, equities analysts forecast that Entera Bio will post -0.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Entera Bio

An institutional investor recently bought a new position in Entera Bio stock. Virtu Financial LLC purchased a new position in shares of Entera Bio Ltd. (NASDAQ:ENTX) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 22,040 shares of the company’s stock, valued at approximately $37,000. Institutional investors own 14.11% of the company’s stock.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.